As many as 30% of patients with schizophrenia respond poorly to antipsychotic medications, with around 7% not responding at all. For patients with treatment-resistant schizophrenia, therapeutic options are more limited, but those options are developing. Because these patients exhibit glutamatergic abnormalities rather than dopaminergic abnormalities, some experts believe that treatment-resistant schizophrenia is a distinct disorder. Other healthcare providers believe that treatment-resistant schizophrenia occupies a more extreme position along a continuum of neurodevelopmental impairment that is etiologically continuous with treatment-responsive forms of schizophrenia. Identification of treatment-resistant schizophrenia practice is often erratic, and clinical management in practice can vary.
Are you prepared to identify and manage treatment-resistant schizophrenia in your patients? Take this quick quiz and learn more.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jeffrey S. Forrest. Fast Five Quiz: Treatment-Resistant Schizophrenia - Medscape - Dec 29, 2023.
Comments